Biopharmaceutical companies FibroGen and AstraZeneca have set up a strategic collaboration to develop and commercialise the oral compound FG-4592, with China as their first option for launching the product, at least two years earlier than any other market, a lawyer involved with the deal said.
“China is working hard, and very effectively, to encourage large multinational corporations and small startups to utilise China contract research organisations, and to develop, trial [or] launch new innovative medicines in China,” Michael Cripps, a Shanghai partner at Clyde & Co, told China Business Law Journal.
Clyde & Co advised FibroGen on all China aspects of the deal, and the firm’s team was led by Cripps.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章，欢迎成为我们的订阅会员成为我们的订阅会员。
